View in EDS

Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.

Saved in:
Bibliographic Details
Title: Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.
Authors: Mallah N; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spain; Department of Preventive Medicine and Institute of Psychology (IPISUS), University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain., Pardo-Seco J; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), and INCIFOR, Universidade de Santiago de Compostela (USC), 15706 Santiago de Compostela, Galicia, Spain., Rodriguez-Tenreiro-Sánchez C; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Giné-Vázquez I; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Mirás-Carballal S; Galician Center for Disease Control and Prevention (CEGACE). Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain., Piñeiro-Sotelo M; Galician Center for Disease Control and Prevention (CEGACE). Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain., Cribeiro-González M; Department of Communicable Diseases, Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain., Conde-Pájaro M; Dirección Xeral de Recursos Económicos, Servizo Galego de Saúde, Xunta de Galicia, Galicia, Spain.Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain., González-Pérez JM; Subdirección de Sistemas y Tecnologías de la Información, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain., Razzini JL; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Rivero-Calle I; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain., Dacosta-Urbieta AI; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain., Harris RC; Sanofi Vaccines, Singapore., Loiacono MM; Department of Epidemiology, University of Delaware, Newark, DE, USA., van Aalst R; Sanofi Vaccines, Morristown, NJ, USA., Farre JM; Sanofi Vaccines, Barcelona, Spain., Dufournet M; Sanofi Vaccines, Lyon, France., Johansen ND; Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Modin D; Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark., Biering-Sørensen T; Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Herlev, Denmark., Duran-Parrondo C; Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain., Martinón-Torres F; Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain; WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain. Electronic address: federico.martinon.torres@sergas.es.
Corporate Authors: GALFLU trial team
Source: Vaccine [Vaccine] 2026 Apr 19; Vol. 79, pp. 128435. Date of Electronic Publication: 2026 Mar 09.
Publication Type: Journal Article; Pragmatic Clinical Trial; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2026.128435